Neuropathic pain is defined as a type of chronic pathological pain that often results from nerve damage or disease. The purinergic receptor P2X is mainly expressed on the cell surface of spinal dorsal horn microglia and is known to be involved in neuropathic pain. Catestatin (CST) is an endogenous peptide derived from chromogranin A. Here, we attempted to identify how CST function in neuropathic pain. Rat model of chronic constriction injury (CCI) was used and experimental results indicated that mechanical and thermal pain sensitivities were significantly increased in CCI rats. The group of CCI rats that received intrathecal CST injection (CCI + CST) exhibited higher P2X mRNA and protein levels compared with the CCI group. Moreover, the phosphorylation level of extracellular signal-regulated kinase 1/2 (ERK1/2) in the CCI + CST group was higher than in the CCI group. This suggested that CST might aggravate neuropathic pain by enhancing P2X receptor expression in spinal microglia, and that the ERK1/2 pathway might be key in the development of neuropathic pain.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.brainresbull.2018.07.003 | DOI Listing |
PLoS One
January 2025
Clinical Research Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America.
Background: Patients receiving chiropractic spinal manipulation (CSM) for spinal pain are less likely to be prescribed opioids, and some evidence suggests that these patients have a lower risk of any type of adverse drug event. We hypothesize that adults receiving CSM for sciatica will have a reduced risk of opioid-related adverse drug events (ORADEs) over a one-year follow-up compared to matched controls not receiving CSM.
Methods: We searched a United States (US) claims-based data resource (Diamond Network, TriNetX, Inc.
Cell Transplant
January 2025
Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neuropathic pain is a debilitating complication following spinal cord injury (SCI). Currently, effective treatments for SCI-induced neuropathic pain are highly lacking. This clinical trial aimed to investigate the efficacy of combined intrathecal injection of Schwann cells (SCs) and bone marrow-derived mesenchymal stem cells (BMSCs) in improving SCI-induced neuropathic pain.
View Article and Find Full Text PDFCurr Pain Headache Rep
January 2025
Department of Anesthesia, Division of Pain Medicine, University of Virginia, Charlottesville, VA, USA.
Purpose Of Review: This paper aims to review pudendal neuralgia pathophysiology, risk factors, diagnosis, and treatment options.
Recent Findings: Conservative and pharmacologic options are first line treatments for the treatment of pudendal neuralgia. Interventional treatment such as, pudendal nerve blocks can be tried if first line treatments feel to provide adequate analgesia.
Curr Pain Headache Rep
January 2025
Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Purpose Of Review: Trigeminal neuralgia (TN) is a highly heterogeneous condition with a wide choice of successful treatment options. However, differences between subtypes are poorly understood and it remains unknown which patients will respond to different treatments. This review aims to summarize the current state of the TN field and explore the problem of predicting surgical outcomes.
View Article and Find Full Text PDFRadiology
January 2025
From the Rush University Medical Center, 1620 W Harrison St, Chicago, IL 60612 (B.H.M., F.G., H.W.A.A., S.G.D., C.D.D., M.A.M.); and University of Texas Health Science Center, Houston, Tex (X.R.Z.).
A 38-year-old previously healthy male patient presented with left-sided facial pain over the prior 5 weeks. He first noticed the pain while washing and applying pressure to his face. The pain was described as shock-like, sharp and shooting, and radiating along the left cheek and temple.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!